Compare Abeona Therapeutics Inc (ABEO) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Skyworks Solutions Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Skyworks Solutions Inc trades at $59.32 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 24.1× Abeona Therapeutics Inc's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SWKS | |
|---|---|---|
Market Cap | $373.32M | $8.99B |
Sector | Health | Technology |
52-Week High | $7.23 | $83.40 |
52-Week Low | $4.17 | $52.50 |
Enterprise Value | $228.22M | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Skyworks Solutions (SWKS) trades at $59.76, down 4.48% on the day, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and net income margins over recent years, though profitability metrics like gross margin remain solid at 41.08%. Recent news highlights product launches in EV and AI infrastructure alongside ongoing legal investigations into corporate governance.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining cash flow and revenue trends pose risks. Investment opportunity lies in market diversification and new tech segments, balanced against margin pressure and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
